Eupraxia Pharmaceuticals Inc. (T:EPRX*CA)
Business Focus: Biotechnology & Medical Research (NEC)
Apr 11, 2024 07:00 am ET
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
VICTORIA, BC, April 11, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024. The meeting is being held in Vienna, Austria from April 18-21, 2024.
Apr 11, 2024 07:00 am ET
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
VICTORIA, BC, April 11, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024. The meeting is being held in Vienna, Austria from April 18-21, 2024.
Apr 08, 2024 07:00 am ET
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
VICTORIA, BC, April 8, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that senior management will deliver a corporate presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto.
Apr 08, 2024 07:00 am ET
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
VICTORIA, BC, April 8, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that senior management will deliver a corporate presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto.
Apr 05, 2024 07:00 am ET
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today
VICTORIA, BC, April 5, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that trading of the Company's common shares will begin today, April 5, 2024, on the Nasdaq Capital Market ("Nasdaq"), under the ticker symbol "EPRX".
Apr 05, 2024 07:00 am ET
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today
VICTORIA, BC, April 5, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that trading of the Company's common shares will begin today, April 5, 2024, on the Nasdaq Capital Market ("Nasdaq"), under the ticker symbol "EPRX".
Apr 03, 2024 05:00 pm ET
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024
Company's Listing Application Approved by Nasdaq
Apr 03, 2024 05:00 pm ET
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024
Company's Listing Application Approved by Nasdaq
Apr 01, 2024 05:00 pm ET
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results
VICTORIA, BC, April 1, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results (prepared in accordance with U.S. GAAP) and operational highlights for the fourth quarter ended December 31, 2023. All amounts are expressed in U.S. dollars unless otherwise indicated.
Apr 01, 2024 05:00 pm ET
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results
VICTORIA, BC, April 1, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced its financial results (prepared in accordance with U.S. GAAP) and operational highlights for the fourth quarter ended December 31, 2023. All amounts are expressed in U.S. dollars unless otherwise indicated.
Mar 15, 2024 08:26 am ET
Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has closed its previously announced overnight marketed public offering (the “Offering”) of common shares of the...
Mar 12, 2024 09:39 am ET
Canadian Investment Regulatory Organization Trade Resumption - EPRX
TORONTO, March 12, 2024 /CNW/ - Trading resumes in:
Mar 12, 2024 09:31 am ET
Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 Million
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced that it has priced its previously announced overnight marketed public offering (the “Offering”) of common shares of the...
Mar 11, 2024 04:08 pm ET
Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company, today announced the launch of an overnight marketed public offering (the “Offering”) of common shares of the Company (the “Shares”) for...
Mar 11, 2024 04:04 pm ET
Canadian Investment Regulatory Organization Trading Halt - EPRX
TORONTO, March 11, 2024 /CNW/ - The following issues have been halted by CIRO:
Feb 05, 2024 04:00 pm ET
Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
No serious or treatment related adverse events in either the first or second cohortSecond cohort demonstrated an average 60% reduction in Dysphasia Likert score and an average 80% reduction in Odynophagia Likert scoreFirst cohort maintaining signs of efficacy to six monthsThird cohort now fully dosed at five times the first cohort dose and two-and-a-half times the second cohort doseResults from third cohort are expected in the second quarter of 2024VICTORIA, BC, Feb. 5, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology compan
Feb 01, 2024 06:00 am ET
Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IAR
Decision to proceed with Phase 3 follows completion of End-of-Phase 2 meeting with the U.S. FDAVICTORIA, BC, Feb. 1, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the Company has initiated its Phase 3 development program for EP-104IAR, the Company's lead drug candidate for the treatment of osteoarthritis ("OA") of the knee, following completion of its End-of-Phase 2 meeting wit
Jan 30, 2024 06:00 am ET
Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the
EP-104IAR demonstrates trends to reduction in joint inflammation and improvement in cartilage quality and morphology compared to placeboVICTORIA, BC, Jan. 30, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced positive magnetic resonance imaging ("MRI") data from the Company's ongoing SPRINGBOARD Study, a Phase 2 randomized, double-blind, vehicle-controlled, parallel-group trial eva
Jan 08, 2024 05:44 pm ET
Eupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf Prospectus
VICTORIA, BC, Jan. 8, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) today announced that it has filed and obtained a receipt for a preliminary multijurisdictional short form base shelf prospectus with the securities regulatory authorities in each of the provinces of Canada, except Québec.
Dec 12, 2023 06:00 am ET
Eupraxia Pharmaceuticals Announces Positive Clinical Data in EP-104GI RESOLVE Trial
Initial low dose presents early efficacy signalsSecond cohort now fully dosed at twice the initial doseFurther results to be disclosed in Q1 2024VICTORIA, BC, Dec. 12, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company, today announced positive clinical data from its Phase 1b/2a RESOLVE trial, which is evaluating safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis ("EoE").
Dec 11, 2023 06:00 am ET
Eupraxia Pharmaceuticals Announces Clinical and Corporate Update
EP-104IAR and EP-104GI continuing to advance clinically & remain on trackCorporate initiatives ongoing to position EP-104IAR and EP-104GI for successful outcomesCompany provides milestones for 2024VICTORIA, BC, Dec. 11, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company, today announced updates for its two clinical programs, EP-104IAR, its lead drug candidate in development for the treatment of knee osteoarthritis ("OA"), and EP-104GI, a high-potential product candidate in development for the treatment of e
Nov 14, 2023 04:01 pm ET
Eupraxia Pharmaceuticals Reports Third Quarter 2023 Financial Results
VICTORIA, BC, Nov. 14, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its financial results (prepared in accordance with International Financial Reporting Standards) and operational highlights for the third quarter ended September 30, 2023. All amounts are expressed in Canadian dollars unless otherwise indicated.
Nov 01, 2023 07:00 am ET
Eupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of Rheumatology
Abstract covering Phase 2 osteoarthritis trial results accepted as a late-breaking submissionVICTORIA, BC, Nov. 1, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology, today announced late-breaking acceptance of the Company's abstract for a poster presentation at the 2023 Annual Meeting of the American College of Rheumatology.
Oct 11, 2023 07:00 am ET
Eupraxia Pharmaceuticals Announces Initiation of Second Cohort in Phase 1b/2a Clinical Trial in Eosinophilic Esophagitis
Preliminary data from the first cohort demonstrates that EP-104GI was well tolerated with no drug-related adverse events reportedVICTORIA, BC, Oct. 11, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology, today announced the initiation of the second cohort for its Phase 1b/2a clinical trial in eosinophilic esophagitis ("EoE").
Sep 11, 2023 03:32 pm ET
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
VICTORIA, BC, Sept. 11, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology, today announced that it will present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York, NY from September 11 to 13, 2023.
Sep 07, 2023 05:00 pm ET
Eupraxia Pharmaceuticals Announces Change of Auditor
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/
Sep 06, 2023 05:00 pm ET
Eupraxia Pharmaceuticals Announces Presentation at PAINWeek 2023
VICTORIA, BC, Sept. 6, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology, today announced that it will present a poster and an oral presentation at PAINWeek 2023, a national conference on pain for healthcare professionals, taking place on September 5-8, 2023, in Las Vegas, NV.
Aug 18, 2023 07:20 pm ET
Eupraxia Pharmaceuticals Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$22,287,125
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/
Aug 11, 2023 05:00 pm ET
Eupraxia Pharmaceuticals Reports Second Quarter 2023 Financial Results
VICTORIA, BC, Aug. 11, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its financial results (prepared in accordance with International Financial Reporting Standards) and operational highlights for the second quarter ended June 30, 2023. All amounts are expressed in Canadian dollars unless otherwise indicated.
Aug 04, 2023 07:00 am ET
Eupraxia Pharmaceuticals Announces a Non-Brokered Private Placement of up to C$22 Million
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/
Jun 26, 2023 07:00 am ET
Eupraxia Pharmaceuticals Reports Positive Topline Data in its Phase 2b Osteoarthritis Trial with EP-104IAR
Met primary and three key secondary endpointsData support clinically meaningful and durable pain reliefPharmacokinetic and safety data support potential for chronic and bilateral dosingCompany to host conference call at 11:00 a.m. ET todayVICTORIA, BC, June 26, 2023 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform, today announced positive results from its Phase 2b clinical trial of EP-104IAR for pain associated with knee osteoarthritis ("OA"). EP-104IAR met its primary end
Jun 26, 2023 07:00 am ET
Eupraxia Pharmaceuticals Reports Positive Topline Data in its Phase 2b Osteoarthritis Trial with EP-104IAR
Met primary and three key secondary endpointsData support clinically meaningful and durable pain reliefPharmacokinetic and safety data support potential for chronic and bilateral dosingCompany to host conference call at 11:00 a.m. ET todayVICTORIA, BC, June 26, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform, today announced positive results from its Phase 2b clinical trial of EP-104IAR for pain associated with knee osteoarthritis ("OA"). EP-104IAR met its primary endpoint w
Jun 15, 2023 06:42 pm ET
Eupraxia Pharmaceuticals Announces Filing of Preliminary Base Shelf Prospectus
VICTORIA, BC, June 15, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) today announced that it has filed and obtained a receipt for a preliminary short form base shelf prospectus with the securities regulatory authorities in each of the provinces of Canada, except Québec.
Jun 13, 2023 07:00 am ET
Eupraxia Pharmaceuticals Receives U.S. FDA Fast Track Designation for EP-104IAR in Treatment of Osteoarthritis
VICTORIA, BC, June 13, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation for the investigation of EP-104IAR in the treatment of adults with osteoarthritis ("OA") of the knee.
Jun 08, 2023 07:00 am ET
Eupraxia Pharmaceuticals Doses First Patient in Phase 1b/2a Eosinophilic Esophagitis Trial
VICTORIA, BC, June 8, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has commenced dosing patients in its phase 1b/2a trial that is evaluating EP-104GI's safety, tolerability and efficacy as a treatment for eosinophilic esophagitis ("EoE").
May 25, 2023 07:00 am ET
Eupraxia Pharmaceuticals Announces Last Patient Last Visit in Phase 2 Osteoarthritis Clinical Trial of EP-104IAR
VICTORIA, BC, May 25, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has reached the last patient last visit in its Phase 2 clinical trial of EP-104IAR for osteoarthritis ("OA").
May 18, 2023 07:00 am ET
Eupraxia Pharmaceuticals Announces Appointment of Dr. Mark Kowalski as Chief Medical Officer
VICTORIA, BC, May 18, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has appointed Mark Kowalski, MD, PhD, as the Company's Chief Medical Officer ("CMO"), effective May 18, 2023.
May 11, 2023 07:00 am ET
Eupraxia Pharmaceuticals Reports First Quarter 2023 Financial Results
VICTORIA, BC, May 11, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the first quarter ended March 31, 2023. All amounts are expressed in Canadian dollars unless otherwise indicated.
Apr 20, 2023 07:00 am ET
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
VICTORIA, BC, April 20, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it will deliver a corporate presentation at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto.
Mar 23, 2023 05:00 pm ET
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2022 Financial Results
VICTORIA, BC, March 23, 2023 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its audited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the fourth quarter and year ended December 31, 2022. All amounts are expressed in Canadian dollars unless otherwise indicated.
Dec 07, 2022 06:00 am ET
Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthritis
- Company remains on track for Phase 2 data readout in Q2 2023 -
Nov 07, 2022 06:00 am ET
Eupraxia Pharmaceuticals Reports Third Quarter 2022 Financial Results
VICTORIA, B.C., Nov. 7, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the third quarter ended September 30, 2022. All amounts are expressed in Canadian dollars unless otherwise indicated.
Nov 01, 2022 07:00 am ET
Eupraxia Pharmaceuticals Appoints Chief Business Officer
--Industry Veteran Paul Brennan Appointed Effective Nov 1st--
Oct 12, 2022 07:00 am ET
Eupraxia Pharmaceuticals Initiates Phase 2 Study in Eosinophilic Esophagitis
-Represents second Phase 2 program for EP-104IAR, with initial data readout anticipated in H1, 2023-
Oct 11, 2022 07:00 am ET
Eupraxia Pharmaceuticals Provides Update for Phase 2 Study in Knee Osteoarthritis for Lead Drug Candidate EP-104IAR
-- Clean Safety Review from Data Safety Monitoring Board Supports Addition of Diabetes Patients into the Trial --
Sep 26, 2022 07:00 am ET
Eupraxia Pharmaceuticals Announces Expansion of Intellectual Property For EP-104IAR
VICTORIA, BC, Sept. 26, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced the grant of a patent and a notice of allowance for EP-104IAR.
Sep 07, 2022 01:00 pm ET
Eupraxia Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
VICTORIA, BC, Sept. 7, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, announced today that its CEO, Dr. James Helliwell, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place on September 12-14, 2022.
Aug 12, 2022 07:00 am ET
Eupraxia Pharmaceuticals Reports Second Quarter 2022 Financial Results
VICTORIA, BC, Aug. 12, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the second quarter ended June 30, 2022. All amounts are expressed in Canadian dollars unless otherwise indicated.
Jul 07, 2022 05:00 pm ET
Eupraxia Pharmaceuticals Recognized as Emerging Life Sciences Company of the Year by Life Sciences British Columbia
VICTORIA, BC, July 7, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, announced today that it has been awarded The Emerging Life Sciences Company of the Year Award by Life Sciences British Columbia ("LSBC").
Jun 08, 2022 07:00 am ET
Eupraxia Pharmaceuticals to Present at BIO International Convention
VICTORIA, BC, June 8, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) a clinical-stage biotechnology company with an innovative drug delivery platform technology, announced today that its CEO, Dr. James Helliwell, will present at the 2022 Bio International Convention being held at the San Diego Convention Center from June 13-16, 2022, in San Diego, CA.
May 05, 2022 05:00 pm ET
Eupraxia Pharmaceuticals Reports First Quarter 2022 Financial Results
VICTORIA, BC, May 5, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the first quarter ended March 31, 2022. All amounts are expressed in Canadian dollars unless otherwise indicated.
Apr 20, 2022 09:39 am ET
IIROC Trade Resumption - EPRX.WT.A
TORONTO, April 20, 2022 /CNW/ - Trading resumes in:
Apr 20, 2022 09:33 am ET
Eupraxia Pharmaceuticals Completes C$14.7 million Overnight Marketed Offering
/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/
Apr 20, 2022 08:23 am ET
IIROC Trading Halt - EPRX.WT.A
TORONTO, April 20, 2022 /CNW/ - The following issues have been halted by IIROC:
Apr 12, 2022 10:02 am ET
IIROC Trade Resumption - EPRX
TORONTO, April 12, 2022 /CNW/ - Trading resumes in:
Apr 12, 2022 09:48 am ET
Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering
Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX:EPRX), is pleased to announce today that it has priced its previously announced overnight marketed public offering (the "Offering"). Pursuant to the Offering, Eupraxia will issue...
Apr 11, 2022 04:03 pm ET
Eupraxia Pharmaceuticals Announces Overnight Marketed Offering
Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX:EPRX), is pleased to announce it has commenced an overnight marketed public offering (the “Offering”) of units (the “Units”) of the Company. The Offering will be conducted on a best...
Apr 11, 2022 03:58 pm ET
IIROC Trading Halt - EPRX
TORONTO, April 11, 2022 /CNW/ - The following issues have been halted by IIROC:
Mar 29, 2022 07:28 pm ET
Eupraxia Pharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
VICTORIA, BC, March 29, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its audited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the fourth quarter and year ended December 31, 2021. All amounts are expressed in Canadian dollars unless otherwise noted.
Jan 06, 2022 06:00 am ET
Eupraxia Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference
VICTORIA, BC, Jan. 6, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, announced today that it will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022.
Dec 13, 2021 04:30 pm ET
Eupraxia Pharmaceuticals Announces Filing of Preliminary Base Shelf Prospectus
VICTORIA, BC, Dec. 13, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, announced today that it has filed and obtained a receipt for a preliminary short form base shelf prospectus with the securities regulatory authorities in each of the provinces and territories of Canada.
Dec 02, 2021 04:00 pm ET
Eupraxia Pharmaceuticals Inc. Provides Update on its Phase 2 Trial for Osteoarthritis Drug Candidate EP-104IAR
Management mitigating risk by adding clinical sites in two countries and making protocol changes Timing for top-line results remains unchanged, still expected in Q4 2022 VICTORIA, BC, Dec. 2, 2021 /CNW/ - December 2, 2021 - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, today provided an update on its ongoing Phase 2 trial that is evaluating the safety and efficacy of its drug candidate EP-104IAR as a treatment for knee osteoarthritis.
Nov 10, 2021 05:54 pm ET
Eupraxia Pharmaceuticals Inc. Reports Third Quarter 2021 Financial Results
VICTORIA, BC, Nov. 10, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the third quarter ended September 30, 2021. All amounts are expressed in Canadian dollars unless otherwise noted.
Nov 04, 2021 07:00 am ET
Eupraxia Pharmaceuticals Inc. Announces Research and Development Funding
VICTORIA, BC, Nov. 4, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced it is receiving advisory services and funding up to $700,000 from the National Research Council of Canada Industrial Research Assistance Program ("NRC IRAP") to support a research and development project to further develop the Company's polymer-based proprietary drug delivery technology.
Sep 16, 2021 05:00 pm ET
Eupraxia Pharmaceuticals Inc. Provides Update for Phase 2 Osteoarthritis Drug Candidate EP-104IAR
EP-104IAR Phase 1 study results published in Osteoarthritis and Cartilage Open Company continues to expand its patent estate for EP-104IAR with patent grant in Israel VICTORIA, BC, Sept. 16, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced an update for its lead osteoarthritis (OA) drug candidate EP-104IAR.
Sep 14, 2021 05:00 pm ET
Eupraxia Pharmaceuticals Inc. Commences Patient Screening For Its Phase 2 Trial For Osteoarthritis Drug Candidate EP-104IAR
Company also reaffirms data readout timelines for its Phase 2 trial VICTORIA, BC, Sept. 14, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced that it has started screening patients for inclusion into its Phase 2 trial, which is evaluating EP-104IAR's efficacy and safety as a treatment for knee osteoarthritis.
Sep 08, 2021 05:00 pm ET
Eupraxia Pharmaceuticals Inc. Announces Presentation at H.C. Wainwright 23rd Annual Global Investment Conference
VICTORIA, BC, Sept. 8, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced that senior management will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference, held virtually September 13-15, 2021.
Aug 13, 2021 05:00 pm ET
Eupraxia Pharmaceuticals Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results
VICTORIA, BC, Aug. 13, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the second quarter ended June 30, 2021. All amounts are expressed in Canadian dollars unless otherwise noted.
Jul 19, 2021 07:00 am ET
Eupraxia Pharmaceuticals Inc. Announces Authorization of Clinical Trial Application for Phase 2 Trial of EP-104IAR in Osteoarthritis of the Knee
VICTORIA, BC, July 19, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced the authorization of its Clinical Trial Application ("CTA") by the Danish Medicines Agency ("DKMA"). The authorization is required to initiate the Company's Phase 2 clinical trial for its lead candidate EP-104IAR as a potential treatment for pain from osteoarthritis ("OA") of the knee.
Jun 21, 2021 05:00 pm ET
Eupraxia Pharmaceuticals Inc. Announces $10 Million Convertible Debt Agreement with Silicon Valley Bank and Conversion of $6.0 Million pre-IPO Debt
VICTORIA, BC, June 21, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has entered into a contingent convertible debt agreement (the "Agreement") with Silicon Valley Bank ("SVB") and concurrently drew down in full the $10 million principal amount under the Agreement. In addition, the Company announces the conversion of approximately $6.0 million of outstanding indebtedness into common shares of the Company ("Common Shares") pursuan
Jun 16, 2021 12:08 pm ET
Eupraxia Pharmaceuticals Inc. Announces Presentation at the Raymond James Human Health Innovations Conference
VICTORIA, BC, June 16, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that senior management will deliver a corporate presentation on June 23, 2021, at 2:00 p.m. ET at the Virtual Raymond James Human Health Innovations Conference.
May 13, 2021 09:15 pm ET
Eupraxia Pharmaceuticals Inc. Provides Corporate Update and Reports First Quarter 2021 Financial Results
VICTORIA, BC, May 13, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its financial results and operational highlights for the first quarter ended March 31, 2021. All amounts are expressed in Canadian dollars unless otherwise noted.
May 03, 2021 07:00 am ET
Eupraxia Pharmaceuticals Inc. Announces Appointment of Bruce Cousins as President & CFO
VICTORIA, BC, May 3, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has appointed industry veteran Bruce Cousins as the Company's new President and Chief Financial Officer.
Apr 14, 2021 05:00 pm ET
Eupraxia Pharmaceuticals Enters Collaborative Partnership with NBCD for Lead Osteoarthritis (OA) Product Candidate
NBCD (Nordic Bioscience Clinical Development) to make strategic investment on the same terms of Eupraxia's recently completed IPO VICTORIA, BC, April 14, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has entered into an agreement (the "CTO Agreement") with NBCD A/S ("NBCD"), a contract research organisation dedicated to clinical drug development and research in OA, to conduct Eupraxia's EP-104IAR Phase 2 clinical trial that will initia
Apr 13, 2021 05:00 pm ET
Eupraxia Pharmaceuticals Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference
VICTORIA, BC, April 13, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that Dr. James Helliwell, President and Chief Executive Officer of Eupraxia will present at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday April 20, 2021 at 4:00 pm ET.
Apr 09, 2021 09:00 am ET
TMX Group Equity Financing Statistics - March 2021
Toronto Stock Exchange, TSX Venture Exchange
Mar 19, 2021 11:30 am ET
Eupraxia Virtually Opens The Market
TORONTO, March 19, 2021 /CNW/ - James Helliwell, President and Chief Executive Officer, Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), and his team joined Dani Lipkin, Director, Global Business Development, TMX Group to celebrate the Company's new listing on Toronto Stock Exchange and open the market.
Mar 09, 2021 08:33 am ET
IIROC Trade Resumption - EPRX
TORONTO, March 9, 2021 /CNW/ - Trading resumes in:
Mar 09, 2021 08:27 am ET
Eupraxia Pharmaceuticals Inc. Completes Initial Public Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
Mar 09, 2021 06:57 am ET
IIROC Trading Halt - EPRX
TORONTO, March 9, 2021 /CNW/ - The following issues have been halted by IIROC:
Mar 03, 2021 03:14 pm ET
Eupraxia Pharmaceuticals Inc. Files Final Prospectus and Announces Pricing of Initial Public Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.